Streetbeat News

Regulatory

NVAX

Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and plans to deliver it during the fall vaccination campaign. If authorized, it would be the only non-mRNA XBB.1.5 vaccine available in the U.S.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 9:36 pm

VEDU

Visionary Education Technology (VEDU) has received a Nasdaq notification regarding a minimum bid price deficiency, putting the company at risk of being delisted if it fails to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 9:31 pm

COIN

iShares Bitcoin Trust has filed an S-1 with the SEC, indicating that Coinbase Custody Trust Company will be the custodian for the trust's Bitcoin holdings.

Portfolio Pulse from Charles Gross

June 15, 2023 | 9:30 pm

LTCH

Latch has regained compliance with Nasdaq's minimum bid price requirement, as its stock price has met the required threshold.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 9:10 pm

HBM

Hudbay Minerals announced that the Supreme Court of British Columbia has approved its plan of arrangement with Copper Mountain. This approval brings the companies closer to finalizing their merger.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 9:02 pm

CBAT

CBAK Energy Technology has received a letter from Nasdaq stating that it has regained compliance with Nasdaq Listing Rule 5550(A)(2).

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:36 pm

SQZ

SQZ Biotechnologies (NYSE:SQZ) has announced a 1-for-10 reverse stock split, effective on July 6, 2023. The company also received a notice from the NYSE for not complying with Section 802.01B due to its average global market capitalization and stockholders' equity being less than $50 million. SQZ plans to submit a plan to cure the deficiency and return to compliance with NYSE listing standards.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:32 pm

CLNN

Clene announced that CNM-Au8 treatment showed a statistically significant reduction in plasma neurofilament light chain levels compared to placebo in the HEALEY ALS Platform Trial. The company plans to discuss the results at an upcoming FDA meeting to accelerate the path toward approval.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:32 pm

CLNN

Clene's CNM-Au8, a gold nanocrystal suspension, showed a statistically significant difference in plasma neurofilament light levels in the HEALEY ALS Platform Trial, indicating potential efficacy in treating ALS.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:30 pm

BKYI

Bio-Key International Inc has filed a prospectus related to the resale of up to 900,000 shares of common stock by a selling stockholder, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:27 pm